This paper reviews the existing evidence supporting the efficacy and safety of rFVIIa in treating bleeding manifestations in patients with thrombocytopenia or those with excessive anticoagulation with warfarin. Currently this is in the form of case report or small series which showed efficacy of rFVIIa in reducing bleeding, shortening of bleeding time or reduction of INR. Large randomized studies are required to prove these points.
– M. Aldouri
NATA: Network for the advancement of Patient Blood Manegement, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and ther heathcare professionals.
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Follow us
Subscribe to our newsletter
- Tutorials
- Resources
- Guides
- Examples
- Docs